Hematology

Latest News

FDA approved. | Image Credit: Pawel - stock.adobe.com

Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS

By Rose McNulty

January 23rd 2025

The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com

High Infection Risk in MM: Insights From the Pre-Immunotherapy Era

January 21st 2025

First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com

Unmet Needs Remain in Secondary AML Following Treatment With HMAs

By Rose McNulty

January 18th 2025

Man donating blood | Image Credit: © New Africa - stock.adobe.com

5 Medications That Defer Blood Donation

By Maggie L. Shaw

January 17th 2025

MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

January 13th 2025

More News

Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma

December 13th 2017

Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma

Stephen Schuster, MD, of the Perelman School of Medicine, provides a summary of results seen with CAR T treatments in leukemia, lymphoma, and myeloma.

Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children

December 12th 2017

Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children

Adolescents and young adults with acute lymphoblastic leukemia (ALL) tend to have worse outcomes than children with ALL, and new research published at the 59th American Society of Hematology Annual Meeting delved into the reasons why, explained Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.

Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care

December 11th 2017

Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care

Patients with blood cancers tend to use hospice care services less frequently overall than patients with solid tumors. While there has been an increase in hospice care use in patients with blood cancers, there has been a failure to increase hospice use meaningfully, according to Thomas LeBlanc, MD, of the Duke Cancer Institute.

Dr Nina Shah on the Benefits of Outpatient HSCT When Possible

December 11th 2017

Dr Nina Shah on the Benefits of Outpatient HSCT When Possible

Providing outpatient hematopoietic stem cell transplant (HSCT) when patients are eligible is a good way to reduce costs, without impacting outcomes, explained Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.

December 11th 2017

CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma

Jaime Rosenberg

Two abstracts at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia found that CTL019 shows promising potential in providing significant benefit and cost effectiveness for pediatric and young adult patients with B-cell acute lymphoblastic leukemia in both the United States and the United Kingdom.

Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines

December 10th 2017

Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines

Physician belief in the art of medicine is running up against the challenge of costs being shifted to patients and health systems and the desire of payers to have less variation in care, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.

Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response

December 10th 2017

Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response

Ibrutinib has the potential to improve vaccine response for patients with chronic lymphocytic leukemia, and an ongoing trial will help provide a better understanding, explained Kerry Rogers, MD, assistant professor, internal medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center.

December 10th 2017

Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care

Surabhi Dangi-Garimella, PhD

During a session on the first day of the 59th Annual Meeting and Exposition of the American Society of Hematology in Atlanta, Georgia, physicians shared current knowledge on cardiovascular toxicities of tyrosine kinase inhibitors (TKIs) as well as the potential for treatment-free remission with these agents.

December 9th 2017

Using Time Spent at Home to Measure End-of-Life Care Quality

Jaime Rosenberg

In a large population of patients who died from hematologic malignancies, the majority spent over 120 days at home in the last 6 months of life. Certain demographic features, such as age and gender, indicate which patients are more likely to die at home and suggest an important role for access to caregiver support, according to an abstract presented at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

December 9th 2017

The Effects of Myeloproliferative Neoplasm Symptoms on Quality of Life

Jaime Rosenberg

A secondary analysis presented at the 59th Annual Meeting of the American Society of Hematology found that all individual symptoms of myeloproliferative neoplasms correlate with quality of life (QoL), and having either 1 severe symptom or having multiple symptoms of moderate intensity was meaningfully correlated with QoL reduction.

December 8th 2017

Significant Economic Burden Associated With Various AML Treatment Episodes

Jaime Rosenberg

Acute myeloid leukemia treatment episodes such as high-intensity chemotherapy, low-intensity chemotherapy, hematopoietic stem cell transplant, and relapsed-refractory patient episodes pose a significant substantial burden, according to an analysis presented at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

December 8th 2017

Patients With AL Amyloidosis From Lower Socioeconomic Status Report Lower Quality of Life

Jaime Rosenberg

Patients with AL amyloidosis from lower socioeconomic status groups, defined in terms of education or employment, conveyed lower health-related quality of life compared to patients with more years of education and/or professional/managerial positions, according to an abstract presented at the 59th Annual Meeting of the American Society of Hematology.

December 7th 2017

Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia

Jaime Rosenberg

An analysis presented at the 59th Annual Meeting of the American Society of Hematology showed that against a 3-year horizon, ibrutinib succeeds in overall survival (OS) and progression free suvrvival (PFS) over hematopoetic stem-cell transplantation (HSCT) in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia with 17p deletion. Against a lifetime horizon, ibrutinib still proved to be superior in OS and PFS over HSCT, but is no longer cost saving as treatment costs continue.

Landmark Study Says Most Patients Don't Benefit From tPA for Post-Thrombotic Syndrome

December 7th 2017

Landmark Study Says Most Patients Don't Benefit From tPA for Post-Thrombotic Syndrome

Allison Inserro

Landmark study shows clot-busting drugs not recommended for most patients with secondary blood clots in the legs.

Systematic Review Finds Elevated Reporting for Thromboembolic Events With JAK Inhibitors

December 5th 2017

Systematic Review Finds Elevated Reporting for Thromboembolic Events With JAK Inhibitors

A systematic review of the FDA’s Adverse Event Reporting System (FAERS) found elevated reporting for both tofacitinib (Xeljanz) and ruxolitinib (Jakafi) for thromboembolic adverse events (AEs), suggesting the possibility of a class-wide issue with Janus kinase (JAK) inhibitors.

December 1st 2017

The Importance of Teamwork in Oncology Care Transitions

Surabhi Dangi-Garimella, PhD

A panel on the importance of clinical and non-clinical stakeholders in a patient’s care trajectory brought together a diverse group of stakeholders at The American Journal of Managed Care®’s Patient-Centered Oncology Care® meeting.

November 30th 2017

African Americans Are More Likely to Have MM, but Are Underrepresented in Research

While African Americans are 3 times more likely than Caucasians to be diagnosed with multiple myeloma (MM)—and twice as likely to die of the disease—they are underrepresented in MM disease research.

Substantial Proportion of Patients Diagnosed With Incident Cancer Have Survived a Prior Cancer

November 28th 2017

Substantial Proportion of Patients Diagnosed With Incident Cancer Have Survived a Prior Cancer

Jaime Rosenberg

A study published in JAMA Oncology found that a significant number of patients newly diagnosed with cancer have had a prior cancer. The prevalence differed among age group and incident cancer type.

Chemotherapy, Radiation Therapy Recommended First for Certain Prostate Cancers, Lymphomas

November 22nd 2017

Chemotherapy, Radiation Therapy Recommended First for Certain Prostate Cancers, Lymphomas

Laura Joszt, MA

Chemotherapy and radiation therapy should be the first line of treatment for certain prostate cancers and lymphomas with a major genetic weakness, according to researchers at the University of Virginia School of Medicine.

A New Target for CAR T Cells Achieves Remission in Resistant Pediatric B-ALL

November 22nd 2017

A New Target for CAR T Cells Achieves Remission in Resistant Pediatric B-ALL

Surabhi Dangi-Garimella, PhD

An early-stage trial in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) has found that modifying the chimeric antigen receptor (CAR) T cells to target the CD22 receptor achieved remission.

Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors

November 15th 2017

Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors

Cyclin-dependent kinase 4/6 inhibitors may have proven benefits for treating metastatic breast cancer, but the therapies are associated with hematological toxicities and febrile neutropenia.

Maximal Tolerated Dose of Hydroxyurea Supported in Children With Sickle Cell Anemia

November 14th 2017

Maximal Tolerated Dose of Hydroxyurea Supported in Children With Sickle Cell Anemia

Recently reported results from Hydroxyurea Study of Long-Term Effects (HUSTLE) support the use of hydroxyurea in children, and indicate that a preferred dosing strategy should target an HbF endpoint of greater than 20%.

Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC

November 8th 2017

Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC

Roche had 2 drugs approved by the FDA—one that is the first approved treatment for a rare blood disease and the other is approved as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non–small cell lung cancer.

Study Investigates the Effects of GSK-3 Inhibition to Improve Understanding of Leukemia

November 7th 2017

Study Investigates the Effects of GSK-3 Inhibition to Improve Understanding of Leukemia

Alison Rodriguez

Research into GSK-3 inhibition in cells may have implications for leukemia treatment.

FDA Accepts BLA For Bayer's Proposed Hemophilia A Treatment

November 1st 2017

FDA Accepts BLA For Bayer's Proposed Hemophilia A Treatment

Bayer has announced the FDA’s acceptance of its Biologics License Application (BLA) for BAY94-9027 for the treatment of hemophilia A in adults and adolescents aged 12 years or older.

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

November 1st 2017

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

Jaime Rosenberg

Mantle cell lymphoma is an aggressive type of non-Hodgkin lymphoma. Acalabrutinib (Calquence) is a kinase inhibitor that works by blocking an enzyme the cancer needs to multiply and spread.

ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen

October 29th 2017

ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen

Alison Rodriguez

Results of the Phase 3 ARROW trial revealed that patiehts with refractory multiple myeloma can live up to 3.6 months longer, without their disease worsening, when Kyprolis (carfilzomib) is administered once-weekly at the 70 mg/m2 dose with dexamethasone rather than Kyprolis administered twice-weekly at the 27 mg/m2 dose with dexamethasone, according to Amgen.

Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities

October 28th 2017

Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities

Alison Rodriguez

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

October 25th 2017

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

Alison Rodriguez

Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.

October 20th 2017

Study: CAR T-Cell Therapy Highly Effective in High-Risk Chronic Lymphocytic Leukemia

CD19 CAR T cells are highly effective in high-risk patients with chronic lymphocytic leukemia who have failed to respond to treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor, according to a new study.

...

17 18 19 20 21 22 23 24 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions